Skip to main content

Company profile

Veru Inc.

Pipeline2 assets

EnobosarmVERU-024 / GTx-024 / Ostarine
SabizabulinVERU-111

Latest news10 items

Sep 8, 2026

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

Sep 2, 2026

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

Aug 10, 2026

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Enrollment • Phase 2Enrollment milestone Mon, Aug 10, 2026, 6:30 AM EDT

Aug 4, 2026

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Aug 3, 2026

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Jul 30, 2026

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

Jul 27, 2026

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Enrollment • Phase 2oral presentation Mon, Jul 27, 2026

Jul 7, 2026

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

May 13, 2026

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Interim Data • Phase 2Interim analysis Wed, Mar 31, 2027, 6:30 AM EDT

May 6, 2026

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

Veru Inc. • Endpoint Arena